Junshi Bio: 2% Share-Sale Plan by 5%+ Shareholder Expires Without Execution

Bulletin Express04-10

Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) announced that the planned shareholding reduction by major shareholder Shanghai Tanying Investment Partnership (LP) has lapsed without any transactions.

Key points:

1. Pre-plan holdings • Shanghai Tanying held 59.46 million A-shares, representing 5.79% of Junshi Bio’s total share capital. • All shares were acquired prior to the company’s IPO and have been freely tradable since 15 July 2021.

2. Reduction plan details • First disclosed on 19 December 2025. • Intended sale: up to 20.53 million shares, equal to 2.00% of total share capital, via block trades. • Planned period: 13 January 2026 to 10 April 2026.

3. Outcome • As of 10 April 2026, Shanghai Tanying had not executed any sales; its shareholding remains at 59.46 million shares (5.79%). • The reduction window has expired, and the plan is now closed.

4. Compliance confirmation • The company stated the non-implementation complies with Shanghai Stock Exchange regulations and the originally disclosed reduction plan.

Junshi Bio’s board affirmed the accuracy and completeness of the disclosed information and noted no violations or early termination of the reduction plan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178256090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178256090","market":"us","top_or_hot":-1,"title":"Junshi Bio: 2% Share-Sale Plan by 5%+ Shareholder Expires Without Execution","media":"Bulletin Express","content":"<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) announced that the planned shareholding reduction by major shareholder Shanghai Tanying Investment Partnership (LP) has lapsed without any transactions.</p>\n<p>Key points:</p>\n<p>1. Pre-plan holdings  \n   • Shanghai Tanying held 59.46 million A-shares, representing 5.79% of Junshi Bio’s total share capital.  \n   • All shares were acquired prior to the company’s IPO and have been freely tradable since 15 July 2021.</p>\n<p>2. Reduction plan details  \n   • First disclosed on 19 December 2025.  \n   • Intended sale: up to 20.53 million shares, equal to 2.00% of total share capital, via block trades.  \n   • Planned period: 13 January 2026 to 10 April 2026.</p>\n<p>3. Outcome  \n   • As of 10 April 2026, Shanghai Tanying had not executed any sales; its shareholding remains at 59.46 million shares (5.79%).  \n   • The reduction window has expired, and the plan is now closed.</p>\n<p>4. Compliance confirmation  \n   • The company stated the non-implementation complies with Shanghai Stock Exchange regulations and the originally disclosed reduction plan.</p>\n<p>Junshi Bio’s board affirmed the accuracy and completeness of the disclosed information and noted no violations or early termination of the reduction plan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Bio: 2% Share-Sale Plan by 5%+ Shareholder Expires Without Execution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Bio: 2% Share-Sale Plan by 5%+ Shareholder Expires Without Execution\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-10 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) announced that the planned shareholding reduction by major shareholder Shanghai Tanying Investment Partnership (LP) has lapsed without any transactions.</p>\n<p>Key points:</p>\n<p>1. Pre-plan holdings  \n   • Shanghai Tanying held 59.46 million A-shares, representing 5.79% of Junshi Bio’s total share capital.  \n   • All shares were acquired prior to the company’s IPO and have been freely tradable since 15 July 2021.</p>\n<p>2. Reduction plan details  \n   • First disclosed on 19 December 2025.  \n   • Intended sale: up to 20.53 million shares, equal to 2.00% of total share capital, via block trades.  \n   • Planned period: 13 January 2026 to 10 April 2026.</p>\n<p>3. Outcome  \n   • As of 10 April 2026, Shanghai Tanying had not executed any sales; its shareholding remains at 59.46 million shares (5.79%).  \n   • The reduction window has expired, and the plan is now closed.</p>\n<p>4. Compliance confirmation  \n   • The company stated the non-implementation complies with Shanghai Stock Exchange regulations and the originally disclosed reduction plan.</p>\n<p>Junshi Bio’s board affirmed the accuracy and completeness of the disclosed information and noted no violations or early termination of the reduction plan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1178256090","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178256090","pubTimestamp":1775822548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) announced that the planned shareholding reduction by major shareholder Shanghai Tanying Investment Partnership (LP) has lapsed without any...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"君实生物：5%以上股东出售2%股份计划到期未执行","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) announced that the planned shareholding reduction by major shareholder Shanghai Tanying Investment Partnership (LP) has lapsed without any transactions.\nKey points:\n1. Pre-plan holdings  \n   • Shanghai Tanying held 59.46 million A-shares, representing 5.79% of Junshi Bio’s total share capital.  \n   • All shares were acquired prior to the company’s IPO and have been freely tradable since 15 July 2021.\n2. Reduction plan details  \n   • First disclosed on 19 December 2025.  \n   • Intended sale: up to 20.53 million shares, equal to 2.00% of total share capital, via block trades.  \n   • Planned period: 13 January 2026 to 10 April 2026.\n3. Outcome  \n   • As of 10 April 2026, Shanghai Tanying had not executed any sales; its shareholding remains at 59.46 million shares (5.79%).  \n   • The reduction window has expired, and the plan is now closed.\n4. Compliance confirmation  \n   • The company stated the non-implementation complies with Shanghai Stock Exchange regulations and the originally disclosed reduction plan.\nJunshi Bio’s board affirmed the accuracy and completeness of the disclosed information and noted no violations or early termination of the reduction plan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178256090","isCrawlerRequest":true}